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Although reperfusion of severely ischemic myocardium
with thrombolytic agents or surgery has shown reduction
in infarct size, the time after coronary occlusion during
which reperfusion can salvage ischemic myocardium is
limited. To determine whether beta-adrenergic blockade
could enhance the salvage of ischemic myocardium by
reperfusion, the left anterior descending coronary artery
was occluded in 18 anesthetized dogs. An in vivo area
at risk was determined by injecting technetium-
99m-labeled albumin microspheres into the left atrium
5 minutes after occlusion and carrying out radioautog-
raphy to define the poorly perfused tissue. Fifteen min-
utes after coronary occlusion, the dogs were randomized
either to a control (saline-treated) group (n = 8) or to
a timolol-treated group (n = 10). Timolol was admin-
istered until a decrease of 20 % in heart rate or blood
After sudden obstruction of a coronary artery, the myocar-
dium perfused by the occluded vessel immediately ceases
to contract. A wavefront of necrosis commences in the sub-
endocardium and for several hours proceeds outward to
reach the subepicardium; in the anesthetized dog, reperfu-
sion carried out within 15 minutes of occlusion generally
salvages all of the ischemic myocardium (1,2). As the time
after occlusion becomes prolonged, the quantity of tissue
salvaged by reperfusion rapidly diminishes, so that by 3
hours only the subepicardial myocardium can be salvaged
by reperfusion (2,3) and by 6 hours essentially all of the
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pressure occurred (mean total dose =0.85 ± 0.22 mg/kg
± standard error of the mean). Coronary occlusion was
maintained for 3 hours and was followed by 3 hours of
reperfusion in both groups. At the end of 6 hours, infarct
size was defined by triphenyltetrazolium chloride stain-
ing and masses of infarct and risk were calculated.
Percent left ventricular mass at risk was similar for
both groups (control = 20.9 ± 2.4%, timolol-treated
= 23.7 ± 2.1%, P = not significant). Mass of necro-
sis/mass at risk was significantly smaller in the timolol-
treated reperfusion group (27.3 ± 2.7 %) versus saline
reperfusion alone (46.5 ± 5.6%) (p < 0.005). Thus,
beta-adrenergic blockade administered early after coro-
nary occlusion results in substantial enhancement of the
salvage achieved by reperfusion alone.
tissue in the area of distribution of the occluded vessel has
become necrotic (4,5). The demonstration that a coronary
thrombus can be lysed by means of intracoronary or intra-
venous streptokinase has led to intense interest in the use
of reperfusion to salvage ischemic myocardium (6-8). As
might be expected from experiments in the dog, it has also
been observed clinically that the time interval after coronary
occlusion during which reperfusion will salvage significant
myocardium is relatively brief. Indeed, most clinical in-
vestigators (7-9) believe that little if any myocardium can
be salvaged if reperfusion is delayed by more than 4 or 5
hours after the onset of the clinical events associated with
infarction. Because it is often difficult for logistic reasons
to carry out reperfusion within this short time interval, it
would be extremely desirable to enhance the quantity of
myocardium salvaged by reperfusion carried out several
hours after coronary occlusion.
Beta-adrenergic blocking agents have been shown to di-
minish the severity of myocardial ischemic injury after coro-
nary occlusion (10-24), although it is unknown whether
these agents alone can actually reduce the mass of the myo-
cardial infarct after a permanent coronary occlusion (25-27).
In view of the salutary effects of beta-adrenergic blockade
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on ischemic myocardium, we wished to determine whether
this intervention might delay cell death sufficiently so as to
enhance the extent of myocardial salvage by reperfusion
carried out several hours after coronary occlusion.
Methods
Experimental preparation. Mongrel dogs of both sexes
weighing between 9 and 27 kg were sedated with acepro-
mazine maleate (1.0 mg/kg body weight subcutaneously),
anesthetized with pentobarbital (30 mg/kg intravenously)
and intubated and placed on a Harvard respirator (Ealing
Co.). A thoracotomy was performed in the fifth left inter-
costal space, the lungs were retracted and the heart was
supported in a pericardial cradle. Polyvinyl catheters were
placed in the femoral vein for fluid and drug administration,
in the femoral artery for blood pressure recording and with-
drawal of microsphere reference samples and in the left
atrium for injection of radioactive microspheres. A micro-
manometer-tipped pressure catheter (Millar Instruments) was
placed into the left ventricle through the apex.
All animals were maintained in accordance with the
guidelines of the Committee on Animals of the Harvard
Medical School and those prepared by the Committee on
Care and Use of Laboratory Animals of the Institute of
Laboratory Animals Resources, National Research Council
(DHEW publication No. [NIH] 78-23, revised 1978).
Experimental protocol. After administration of lido-
caine (1.5 mg/kg intravenously), the left anterior descending
coronary artery was occluded with a Schwartz vascular clamp.
A second similar dose of lidocaine was administered 5 min-
utes after coronary artery occlusion. Five minutes after oc-
clusion, 600,000 technetium-99m-Iabeled human albumin
microspheres (dose 0.54 mCi/kg) were injected slowly into
the left atrium for determination of area at risk by autora-
diography as previously described by DeBoer et al. (4).
Radioactive plastic microspheres (cerium-141 , scandium-46,
stannum-l13) were injected for determination of regional
myocardial blood flow 10 minutes after occlusion, as pre-
viously described (28). Fifteen minutes after coronary oc-
clusion the dogs were randomized either to a control group
(n = 8) receiving saline infusion or to a group (n = 10)
treated with timolol maleate (Merck Sharp and Dohme,
Research Lab) until a decrease of approximately 20% in
heart rate or systolic arterial pressure was detected (mean
total dose 0.85 ± 0.22 mg/kg ± standard error of the
mean). Coronary occlusion was maintained for 3 hours and
was followed by 3 hours of reperfusion by releasing the
clamp in both groups. Heart rate and arterial and left ven-
tricular pressure were continuously recorded before occlu-
sion, throughout occlusion and during reperfusion periods.
Echocardiographic analysis. Two-dimensional echo-
cardiograms were obtained from the open chest dogs with
an ATL Mark III model echocardiograph with an 850A real
time scan controller. Images were recorded on Scotch (3M)
videocassettes with a Panasonic NV-8200 recorder. A
saline-filled glove was placed between the epicardium and
the transducer to place the epicardial surface within the focal
zone. Short-axis echocardiographic images were traced di-
rectly from the video display (ATL 315A) from a stop-frame
analysis of three consecutive cardiac cycles. These tracings
were taken at end-diastole and end-systole with the onset
of the Q wave in lead II to define end-diastole and the peak
of the T wave to define end-systole. The images were traced
by an investigator who was unaware of the treatment the
dogs had received. Short-axis images for calculation were
taken from the center of the infarcted zone, which was
clearly visible at the level of the papillary muscles. For
studies of short-axis change, end-diastolic area was mea-
sured by planimetry from the maximal short-axis cross sec-
tion at the end of diastole; end-systolic area was determined
at the same location.
Percent chnnge of area (% /lA) was calculated as follows:
% IlA = (EDA - ESA)/EDA,
where EDA = end-diastolic area and ESA = end-systolic
area. Two-dimensional echocardiograms were obtained 2
hours after occlusion and toward the end of the experiment.
Postmortem studies. The animals were killed with an
overdose of potassium chloride to arrest the heart in diastole
and the heart was excised. The left ventricle was dissected
free, and its surfaces sprayed with liquid Freon to allow
easy sectioning; the left ventricle was then sectioned parallel
to the atrioventricular groove in 5 mm transverse slices.
The size of the myocardial infarct was determined by
incubation in 1% triphenyltetrazolium chloride for 10 min-
utes at 37°C. Infarcted myocardium appears pale gray, whereas
normal myocardium stains deep brick red (29,30). Auto-
radiography of each myocardial section was performed as
previously described (4). With this technique, normally per-
fused myocardium appears as an area of increased radio-
graphic density, whereas ischemic areas appear as clearly
demarcated zones of decreased radiographic density ("cold
spot images"). Tracings of each heart section were super-
imposed on the autoradiograph and the border of the isch-
emic area at risk was drawn at the edge of the zone of
decreased radiographic density. The areas of necrosis and
risk were determined by planimetry and corrected to the
weight of the heart slices and expressed as mass of necrosis
and mass at risk; infarct size was expressed as mass of
necrosis as a percent of the mass at risk.
Statistical analysis. Unpaired t tests were used to cal-
culate the significance of differences of masses of necrosis
and risk, hemodynamic measurements and echocardio-
graphic data between the groups. Values were expressed as
mean ± standard error of the mean.
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Results
Twenty-seven dogs were entered into the protocol. Seven
dogs developed ventricular fibrillation shortly after occlu-
sion before randomization and died. One dog in the control
group developed hypotension and died 30 minutes after
occlusion. Another dog in the timolol-treated group required
multiple defibrillations and was excluded from the study.
Of the remaining 18 dogs that survived for 6 hours, 8 were
in the control group (reperfusion alone) and 10 were in the
treated group (timolol plus reperfusion).
Assessment of myocardial salvage (Fig. 1). Percent
left ventricular mass at risk as assessed by autoradiography
was similar in both groups (control 20.9 ± 2.4% and
timolol-treated 23.7 ± 2.1%, probability [p] "" not sig-
nificant [NS]). Mass of necrosis expressed as a percent of
mass at risk was 46.5 ± 5.6% in the control group and
significantly smaller, 27.3 ± 2.7%, in the timolol-treated
group (p < 0.005). Thus, timolol treatment followed by
myocardial reperfusion results in substantial enhancement
of myocardial salvage achieved by reperfusion alone.
Regional myocardial blood flow. Five minutes after
occlusion, subendocardial and subepicardial flows were similar
in both groups; in the ischemic zone these values were 0.18
± 0.04 and 0.33 ± 0.11 mllmin per g, respectively, in the
control group and 0.16 ± 0.05 and 0.20 ± 0.11 in the
timolol-treated group (p "" NS between corresponding re-
gions in the two groups). In the nonischemic zone, sub-
endocardial and subepicardial flows were 1.18 ± 0.11 and
0.88 :±: 0.12, respectively, in the control group and 1.52
± 0.46 and 1.18 ± 0.22 in the timolol-treated group
(p "" NS).
Hemodynamic measurements (Table 1, Fig. 2). Mean
heart rate in the preocclusion period was similar in both
groups (140 ± 8 beats/min) in the control group and 141
Figure 1. Percent mass of necrosis over mass at risk for .control
dogs (closed circles) and for timolol-treated dogs (open cIrcles).
Circles with bars are mean values ± standard error of the mean.
Differences between the two groups were significant (p < 0.005).
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± 7 in the timolol-treated group (before treatment) (p ""
NS). The percent decrease in heart rate in the timolol-treated
group was 15.6 ± 3.2% at 2 hours after occlusion; in the
control group the decrease was significantly less (5.4 ±
3.4%) (p < 0.05). Mean systolic pressure before occlusion
was 114.8 ± 8.4 mm Hg in the control group, and 125.3
± 8.3 in the timolol-treated group (before treatment) (p ""
NS). The percent decrease in systolic pressure was signif-
icantly greater in the timolol-treated group (22.6 ± 3.3%)
than in the control group (9.2 :±: 3.1 %) (p < 0.01). The
rate-pressure product (heart rate x peak systolic pressure)
decreased from preocclusion values by a mean of 35.1 ±
2.9% in the timolol-treated group at 2 hours after occlusion;
in the control group the decrease was smaller, 14.5 ± 2.6%
(p < 0.001). Although left ventricular end-diastolic pressure
tended to be higher in the timolol-treated group, this dif-
ference did not approach statistical significance.
Echocardiographic measurements. Echocardiographic
measurements were obtained at 2 hours after occlusion and
5 to 6 hours after occlusion (2 to 3 hours of reperfusion) in
seven control and nine timolol-treated dogs. Short-axis area
change calculated from images at the center of the infarct
at 2 hours after occlusion was 27.5 ± 4.7% in the control
group and 34.6 :±: 2.8% in the timolol-treated group (p ""
NS). Postreperfusion (2 to 3 hours) short-axis area change
was 30.4 ± 4.3% for the control group and 36.9 ± 2.8%
for the timolol-treated group (p "" NS). Thus, the beta-
adrenergic blocking actions of timolol did not cause sig-
nificant impairment of regional function.
Discussion
Recently, it has become apparent that early restoration
of blood flow after coronary occlusion may result in limi-
tation of myocardial necrosis in patients with evolving myo-
cardial infarction (6-8). The rate of progression of necrosis
may be influenced by the residual collateral circulation to
the ischemic zone as well as hemodynamic and metabolic
factors affecting myocardial oxygen demand. Because there
is an inevitable delay between the clinical events usually
signifying myocardial infarction and the time at which myo-
cardial reperfusion can be started, the possibility of com-
bining a pharmacologic intervention that reduces myocardial
oxygen demands with myocardial reperfusion was considered.
Beneficial effects of timolol. The present study dem-
onstrates that beta-adrenergic blockade achieved by early
timolol administration followed by myocardial reperfusion
results in substantial enhancement of myocardial salvage
achieved by reperfusion alone; the percent of myocardium
salvaged by reperfusion 3 hours after coronary occlusion
increased from an average of 53% in the control dogs to
73% in the dogs treated with timolol 15 minutes after coro-
nary occlusion and reperfused 3 hours later.
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+20 Heart Rate adrenergic blocking activity varies widely, and no simple
relation exists between the dose of timolol, the plasma level
and the therapeutic activity. Therefore, in our study timolol
was administered not as a fixed dose, but according to a
predefined hemodynamic response. This enabled us to de-
termine the optimal dose for decreasing oxygen demands
without causing deleterious hemodynamic effects. Experi-
mental and clinical studies (31,32) have demonstrated that
timolol reduces heart rate, left ventricular contractility and
indexes of cardiac work.
Experimental studies in cats (33) have shown that timolol
can protect ischemic myocardium as reflected in a reduced
release of myocardial creatine kinase activity and reduction
in ST segment elevation after coronary occlusion. Under
controlled hemodynamic conditions, timolol appears to im-
prove perfusion of the normal myocardium, whereas blood
flow to ischemic tissue remains unchanged (34). Timolol
has been reported to exert an antianginal effect in patients
(35) and reduce mortality and reinfarction rates in those
surviving acute myocardial infarction (36). However, not
all beta-adrenergic blocking agents have been shown to have
a beneficial effect on infarct size. In some studies (37,38),
propranolol did not reduce infarct size.
Effects of timoIol on regional function. An important
question was how beta-adrenergic blockade affects regional
function of the jeopardized zone. Whereas the negative
inotropic effects exerted by beta-adrenergic blockade would
be expected to impair function, the increase in tissue salvage
induced by the beta-blocker might be expected to enhance
ventricular function despite the anticipated postischemic
depression of left ventricular function, that is, "stunning"
of the myocardium (39). These two opposing influences
appeared to balance each other and regional function did
not differ in the control and timolol-treated groups when
measurements were made at 2 hours after occlusion and at
the end of the reperfusion period. We observed previously
o Timolol
Systolic Arterial Pressure
Double Product
• Control
I !
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Timolol maleate is a beta-adrenoreceptor blocking drug
that lacks both intrinsic sympathomimetic activity and mem-
brane stabilizing properties (31). The drug's half-life in
plasma is approximately 3 to 4 hours. The level of beta-
Figure 2. Percent change from preocclusion (100%). Values from
top to bottom are for heart rate, systolic arterial pressure and double
product (heart rate x systolic arterial pressure). Closed circles
with bars are mean values ± standard error of the mean for control
dogs; open circles with bars are mean values ± standard error
of the mean for timolol-treated dogs.
Table 1. Hemodynamic Data*
Preocclusion
2 Hours
Postocclusion
6 Hours Postocclusion
(3 hours
postreperfusion)
Heart rate (beats/min)
Control
Timolol
Systolic pressure (mm Hg)
Control
Timolol
Left ventricular end-diastolic pressure (mm Hg)
Control
Timolol
139.8 ± 7.5
141.0 ± 7.0
114.8 ± 8.4
125.3 ± 8.3
6.0 ± 0.7
4.6 ± 1.0
132.0 ± 8.0
118.3 ± 6.4
102.9 ± 4.6
95.3 ± 3.9
7.3 ± 1.2
11.4 ± 4.4
127.0 ± 7.8
111.6 ± 8.1
101.4 ± 4.4
101.0 ± 2.3
8.8 ± 2.2
9.0 ± 4.1
*The differences by grouped t test were not statistically significant in each time period between groups.
Data are presented as mean values ± standard error of the mean. When data were expressed as percent change
from preocclusion values, there were significant differences between the two groups (see text and Fig. 2).
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(40) that although seriously ischemic tissue exhibits delayed
postischemic recovery of function and high energy phos-
phate metabolism, significant recovery does, in fact, ulti-
mately occur. In dogs subjected to 2 hours of coronary
occlusion and 2 weeks of reperfusion, active left ventricular
wall thickening occurs after 3 days of reperfusion (40).
Other studies have shown that brief 15 minute temporary
periods of ischemia not associated with necrosis result in
substantial depression of adenosine triphosphate for at least
72 hours after reperfusion (41); however, adenosine tri-
phosphate is fully recovered by 7 days (42). Therefore, it
is likely that had functional measurements been made I to
2 weeks after reperfusion, the salvaged myocardium would
have been superior in the dogs treated with timolol and
reperfusion with their smaller infarcts.
Clinical implications. Beta-adrenergic blockade with
timolol begun shortly after coronary occlusion followed by
reperfusion resulted in substantial enhancement of myo-
cardial salvage compared with reperfusion alone. Beta-
adrenergic blockade might augment the quantity of tissue
salvaged by reperfusion carried out early (within 4 hours elf
the coronary occlusion) and/or prolong the time interval after
occlusion during which reperfusion may salvage severely
ischemic myocardium that would otherwise be expected to
undergo necrosis.
No animal model can exactly mimic the clinical situation;
however, these observations have interesting clinical im-
plications. The immediate administration of cardioprotec-
tive drugs, such as beta-adrenergic blocking agents, calcium
channel antagonists or a variety of other agents that can
delay cell death (0), might be desirable in patients with
evolving myocardial infarction who are candidates for coro-
nary reperfusion. Although in our study timolol was ad-
ministered earlier after coronary occlusion than occurs in a
clinical setting, the data have clinical relevance because
there is a large group of patients with evolving myocardial
infarction who are already receiving long-term beta-block-
ing therapy for angina and hypertension. In addition, there
are now a group of patients at high risk of acute myocardial
infarction who might receive beta-adrenergic blocking drugs
prophylactically, especially if they have already had a pre-
vious infarction. Our results suggest that it is worth pursuing
experiments in which beta-adrenergic blockade is admin-
istered a few hours after occlusion but before reperfusion
to mimic current clinical coronary reperfusion studies.
We gratefully acknowledge the technical assistance of Kevin J. Alker and
the secretarial assistance of Nancy Watterson-Diorio.
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